Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 135 Carcinoma, Hepatocellular 80 Neoplasms 52 Small Cell Lung Carcinoma 50 Breast Neoplasms 50 Lung Neoplasms 44 Triple Negative Breast Neoplasms 41 Melanoma 38 Colorectal Neoplasms 38 Carcinoma, Transitional Cell 37 Urinary Bladder Neoplasms 33 Neoplasm Metastasis 32 Carcinoma, Renal Cell 29 Ovarian Neoplasms 20 Uterine Cervical Neoplasms 19 Stomach Neoplasms 17 Squamous Cell Carcinoma of Head and Neck 17 Head and Neck Neoplasms 15 Liver Neoplasms 14 Prostatic Neoplasms 12 Glioblastoma 12 Solid Tumors 11 Recurrence 11 Sarcoma 10 Esophageal Neoplasms 10 Pancreatic Neoplasms 9 Lymphoma 9 Kidney Neoplasms 9 Endometrial Neoplasms 9 Mesothelioma, Malignant 8

Interventions

Etoposide 3 Carboplatin 3 Paclitaxel 2 sintilimab 1 pembrolizumab 1 olaparib 1 ceralasertib 1 atezolizumab 1 apatinib 1 anlotinib 1 Topotecan 1 Platinum 1 Immune Checkpoint Inhibitors 1 Drug Therapy 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

SCLC × atezolizumab × Clear all

NCT06179069 2026-04-03

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

Zai Lab (Hong Kong), Ltd.

Phase 1 Recruiting

SCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡